Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

884
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
884
Esophageal Varices-I: Introduction01:24

Esophageal Varices-I: Introduction

2.4K
Esophageal varices are dilated, tortuous veins which are found mainly in the submucosa of the lower esophagus but which may also appear higher up or extend into the stomach. They develop due to increased pressure in the portal venous system, often as a result of liver cirrhosis. This condition scars and damages the liver, impeding normal blood flow through the portal vein. To compensate, blood seeks alternative pathways, forming fragile new vessels (varices) in the esophagus and stomach. These...
2.4K
Barrett Esophagus-II: Clinical Manifestations and Management01:21

Barrett Esophagus-II: Clinical Manifestations and Management

1.8K
Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
1.8K
Esophageal Strictures-II: Clinical Features and Management01:26

Esophageal Strictures-II: Clinical Features and Management

1.1K
Patients with esophageal strictures often experience a range of symptoms. Initially, they may have difficulty swallowing solid foods, which can progress to include liquids. Additional symptoms may involve chest pain or discomfort, regurgitating food and fluids, heartburn, unintentional weight loss, coughing or choking during meals, and hoarseness.
Healthcare providers should gather a comprehensive medical history and conduct a physical examination for diagnosis. If esophageal stricture is...
1.1K
Gastroesophageal Reflux Disease II: Clinical Features and Management01:29

Gastroesophageal Reflux Disease II: Clinical Features and Management

1.1K
Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
1.1K
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

2.3K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
2.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hepatic Venous Pressure Gradient, Noninvasive Tests, and Prognosis Across the Subtypes of Advanced Steatotic Liver Disease.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

Reply to: Sex for the purposes of MELD 3.0 calculation: When this differs from birth sex and implications for policy.

Hepatology communications·2026
Same author

Prognostic value of factor VIII, D-dimer and high molecular risk variants assessing re-thrombosis risk in non-cirrhotic portal vein thrombosis.

JHEP reports : innovation in hepatology·2026
Same author

Corrigendum to 'Pre-emptive TIPS should be considered in high-risk patients with both acute variceal bleeding and severe alcohol-related hepatitis<sup>'</sup> (JHEP Reports 7 [2025] 101611).

JHEP reports : innovation in hepatology·2026
Same author

Prevalence of Active HCV Infection in Spain in 2022 Using Multiparameter Evidence Synthesis.

Journal of viral hepatitis·2026
Same author

Biological therapies for inflammatory pouch disorders: insights and outcomes from the RESERVO study of GETECCU.

Therapeutic advances in gastroenterology·2026

Related Experiment Video

Updated: May 1, 2026

Endoscopic Injection Sclerotherapy Assisted by Cyanoacrylate and Clips for Gastroesophageal Varices
04:09

Endoscopic Injection Sclerotherapy Assisted by Cyanoacrylate and Clips for Gastroesophageal Varices

Published on: June 13, 2025

1.8K

Secondary prophylaxis for esophageal variceal bleeding.

Agustín Albillos1, Marta Tejedor2

  • 1Department of Gastroenterology and Hepatology, Hospital Universitario Ramón y Cajal, CIBERehd, IRYCIS, University of Alcalá, Ctra. Colmenar km. 9.100, Madrid 28034, Spain.

Clinics in Liver Disease
|April 1, 2014
PubMed
Summary

Combination therapy using beta-blockers and endoscopic band ligation (EBL) effectively prevents esophageal variceal rebleeding in cirrhosis. Beta-blockers are crucial, offering broader benefits beyond variceal bleeding prevention.

Keywords:
Endoscopic band ligationHemodynamic respondersSecondary prophylaxisTransjugular intrahepatic portosystemic shunt (TIPS)Variceal rebleedingβ-blockers

More Related Videos

Underwater Endoscopic Injection Sclerotherapy for Gastroesophageal Varices
02:14

Underwater Endoscopic Injection Sclerotherapy for Gastroesophageal Varices

Published on: August 1, 2025

2.2K
Laparoscopic Splenectomy with Pericardial Devascularization for Hypersplenism and Esophageal Variceal Hemorrhage Due to Portal Hypertension
04:00

Laparoscopic Splenectomy with Pericardial Devascularization for Hypersplenism and Esophageal Variceal Hemorrhage Due to Portal Hypertension

Published on: November 15, 2024

1.1K

Related Experiment Videos

Last Updated: May 1, 2026

Endoscopic Injection Sclerotherapy Assisted by Cyanoacrylate and Clips for Gastroesophageal Varices
04:09

Endoscopic Injection Sclerotherapy Assisted by Cyanoacrylate and Clips for Gastroesophageal Varices

Published on: June 13, 2025

1.8K
Underwater Endoscopic Injection Sclerotherapy for Gastroesophageal Varices
02:14

Underwater Endoscopic Injection Sclerotherapy for Gastroesophageal Varices

Published on: August 1, 2025

2.2K
Laparoscopic Splenectomy with Pericardial Devascularization for Hypersplenism and Esophageal Variceal Hemorrhage Due to Portal Hypertension
04:00

Laparoscopic Splenectomy with Pericardial Devascularization for Hypersplenism and Esophageal Variceal Hemorrhage Due to Portal Hypertension

Published on: November 15, 2024

1.1K

Area of Science:

  • Hepatology
  • Gastroenterology
  • Clinical Medicine

Background:

  • Esophageal variceal rebleeding is a major complication of cirrhosis and portal hypertension.
  • Combination therapy with beta-blockers and endoscopic band ligation (EBL) is the standard prophylactic approach.
  • Beta-blockers offer systemic benefits for portal hypertension complications beyond variceal bleeding.

Purpose of the Study:

  • To evaluate the efficacy of combination therapy for esophageal variceal rebleeding prophylaxis.
  • To elucidate the role of beta-blockers and EBL in preventing rebleeding.
  • To identify patient subgroups that may benefit from alternative or earlier interventions like transjugular intrahepatic portosystemic shunt (TIPS).

Main Methods:

  • The study reviews existing data on combination therapy for esophageal variceal rebleeding.
  • Analysis focuses on the additive benefits of beta-blockers to EBL versus EBL to beta-blockers.
  • Consideration of transjugular intrahepatic portosystemic shunt (TIPS) as a rescue or alternative first-line therapy.

Main Results:

  • Combination therapy with beta-blockers and EBL significantly reduces esophageal variceal rebleeding.
  • The addition of beta-blockers to EBL is more effective than adding EBL to beta-blockers, due to EBL's risk of post-banding ulcer bleeding.
  • Transjugular intrahepatic portosystemic shunt (TIPS) is effective as a rescue treatment.

Conclusions:

  • Combination therapy is the standard for preventing esophageal variceal rebleeding.
  • Beta-blockers are the cornerstone of this therapy due to their wide-ranging benefits in portal hypertension.
  • TIPS should be considered for specific patient groups, including those with refractory ascites or fundal varices, or those who bleed initially despite beta-blocker therapy.